Search

Displaying results 3361 - 3370 of 10000 in total
  1. Drug

    Plicamycin

    go.drugbank.com/drugs/DB06810
    ApprovedWithdrawn

    Plicamycin is an antineoplastic antibiotic produced by Streptomyces plicatus. … It has been used in the treatment of testicular cancer, Paget's disease of bone, and, rarely, the management of hypercalcemia. The manufacturer discontinued plicamycin in 2000.

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Lasofoxifene

    go.drugbank.com/drugs/DB06202
    ApprovedInvestigationalWithdrawn

    Lasofoxifene is a non-steroidal 3rd generation selective estrogen receptor modulator (SERM) that selectively binds to both ERα and ERβ with high affinity. … It gained approval by European Commission in March 2009.

    Categories: Selective Estrogen Receptor Modulators
  3. Drug

    Lubiprostone

    go.drugbank.com/drugs/DB01046
    ApprovedInvestigational

    Lubiprostone is a medication used in the management of idiopathic chronic constipation. … A prostaglandin E1 derivative, lubiprostone is a bicyclic fatty acid that activates ClC-2 chloride channels located on the apical side of the gastrointestinal epithelial cells.

  4. Drug

    Emricasan

    go.drugbank.com/drugs/DB05408
    Investigational

    It is developed by Pfizer and made in such a way that it protects liver cells from excessive apoptosis. … Emricasan is the first caspase inhibitor tested in human which has received orphan drug status by FDA.

  5. Drug

    Thiothixene

    go.drugbank.com/drugs/DB01623
    Approved

    A thioxanthine used as an antipsychotic agent. Its effects are similar to the phenothiazine antipsychotics.

    Categories: Dopamine D2 Receptor Antagonists, Serotonin Receptor Antagonists
  6. Drug

    INS 316

    go.drugbank.com/drugs/DB05390
    Experimental

    It is selective P2y2 receptor antagonists claimed to be useful as anti-inflammatory agents. … INS316 belongs to the family of drugs called nucleoside triphosphates.It is studied in the diagnosis of lung diseases, including lung cancer.

  7. Drug

    Dexloxiglumide

    go.drugbank.com/drugs/DB04856
    Investigational

    Dexloxiglumide is a selective cholecystokinin type A (CCKA) receptor antagonist in phase III testing by Rottapharm in Europe only, as U.S. trials have been discontinued. … As the D-isomer of loxiglumide, it retains all pharmacological properties of loxiglumide but is more potent.

  8. Drug

    Tisagenlecleucel

    go.drugbank.com/drugs/DB13881
    ApprovedInvestigational

    Tisagenlecleucel is an immunocellular therapy that involves autologous T cells that are collected from each individual patient and genetically engineered to express a specific protein called a chimeric … It was granted approval by FDA in August 2017 under the market name Kymriah.

    Categories: CD19 Receptor Interactions, CD19-directed Chimeric Antigen Receptor
  9. Drug

    Ceruletide

    go.drugbank.com/drugs/DB00403
    Approved

    Caerulein is a specific decapeptide similar in action and composition to the natural gastrointestinal peptide hormone cholecystokinin. … It exerts stimulatory effects on the gastric, biliary, and pancreatic secretion, as well as on certain smooth muscles.

  10. Drug

    Propylhexedrine

    go.drugbank.com/drugs/DB06714
    Approved

    Propylhexedrine is an alpha-adrenergic agonist often used in nasal decongestant inhalers. It is used to give temporary relief for nasal congestion from colds, allergic rhinitis, or allergies.